trending Market Intelligence /marketintelligence/en/news-insights/trending/JcWKEQr_rw7CLPjcYCDQAQ2 content esgSubNav
In This List

Cellectar Biosciences receives patent protection for cancer drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Cellectar Biosciences receives patent protection for cancer drug

Cellectar Biosciences Inc. received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as well as associated cancer stem cells.

The patent protection will last through the end of 2035.